{
    "nct_id": "NCT06111235",
    "official_title": "A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)",
    "inclusion_criteria": "* Pathologically confirmed IR-NMIBC, per American Urologic Association/Society of Urologic Oncology/National Comprehensive Cancer Network guidelines, within 90 days of participant randomization:\n\n  1. Recurrent LG Ta within 12 months of prior LG or HG (HG Ta ≤ 3 cm) tumor\n  2. Solitary LG Ta >3 cm tumor\n  3. Multifocal LG Ta tumors\n  4. Primary and solitary HG Ta ≤3 cm tumor\n  5. LG T1 tumor\n* All visible disease removed by TURBT within 12 weeks of study randomization\n* Acceptable baseline organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* High-risk NMIBC (e.g., HG T1, Recurrent or multifocal HG Ta>3cm tumor(s), CIS)\n* Low-Risk NMIBC (e.g., solitary LG Ta ≤3 cm tumor)\n* Disease in the prostatic urethra at any time or in the upper genitourinary tract within 24 months of randomization\n* Muscle-invasive bladder cancer, locally advanced or metastatic bladder cancer\n* Prior treatment with any human adenovirus serotype 5 based therapy (e.g., Ad-interferon or Adstiladrin)",
    "miscellaneous_criteria": ""
}